Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences Stock: Beats Its Own Guide Total second-quarter revenue climbed 12% to $699.3 million, above expectations for $690 million and Exact's own guidance for $677 million to $697 million ...

Exact Sciences Corp EXAS Stock XNAS Rating as of Aug 1, 2025 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends Ownership Executive ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.

A n updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in a massive study, triggering fewer false alarms than its current product, the ...

Summary According to ARK’s research, Exact Sciences has been a pioneering force in the growing field of oncology testing and will likely remain so during the next five years. Exact’s ...

Review the current valuation for Exact Sciences Corp (EXAS:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.